AdipotidevsPemvidutide

Adipotide uses a fundamentally different approach to fat reduction compared to appetite suppressants or metabolic modulators — it physically destroys the blood supply feeding white adipose tissue. The molecule is a chimeric peptidomimetic with two functional domains: a targeting peptide (sequence CKGGRAKDC) that homes to blood vessels in white fat, and a pro-apoptotic peptide (D(KLAKLAK)2) that kills the cells it enters.

The targeting sequence binds specifically to prohibitin, a protein expressed on the luminal surface of endothelial cells in the vasculature supplying white adipose tissue but not other organ systems. This vascular address system means adipotide accumulates selectively in fat tissue blood vessels. Once bound, the molecule is internalized into the endothelial cells, where the pro-apoptotic D(KLAKLAK)2 domain disrupts mitochondrial membrane integrity, triggering programmed cell death.

As the blood vessels supplying fat deposits are destroyed, the adipose tissue they serve undergoes ischemic cell death and is gradually reabsorbed by the body. In rhesus monkey studies, adipotide treatment produced significant reductions in body weight and waist circumference, with measurable decreases in white fat mass on imaging. However, the approach carries inherent risks — the targeting is not perfectly specific, and prohibitin expression in renal vasculature led to significant kidney toxicity in primate studies, which has severely limited clinical development.

Pemvidutide (ALT-801) is a once-weekly subcutaneous dual GLP-1 and glucagon receptor agonist, mechanistically similar to mazdutide and survodutide but with a distinct molecular design and a primary development focus on metabolic dysfunction-associated steatohepatitis (MASH) alongside obesity. The dual mechanism combines appetite suppression with enhanced energy expenditure and direct hepatic fat mobilisation.

The GLP-1 receptor component drives the established central appetite suppression through hypothalamic and brainstem signalling, slows gastric emptying, and stimulates glucose-dependent insulin secretion. The glucagon receptor agonism component is what differentiates pemvidutide from pure GLP-1 drugs — glucagon binding in hepatocytes activates adenylyl cyclase and protein kinase A, driving up fatty acid beta-oxidation and ketogenesis while reducing de novo lipogenesis. This directly mobilises stored hepatic triglycerides for energy use rather than continued storage, addressing the core pathology of MASH. In adipose tissue and beyond, glucagon signalling also raises whole-body energy expenditure through thermogenic and futile-cycle mechanisms.

The receptor potency ratio is balanced so that glucagon-driven hepatic glucose output is offset by GLP-1-driven insulinotropic effects, yielding net glycemic improvement alongside enhanced fat oxidation. Phase 2b results in obesity demonstrated approximately 15.6% mean body weight loss at 48 weeks, and parallel MASH trials showed significant reductions in liver fat content alongside improvements in fibrosis markers. Phase 3 trials in both obesity and MASH are now underway, positioning pemvidutide as Altimmune's lead asset and a competitor to mazdutide and survodutide in the dual GLP-1/glucagon class.